论文部分内容阅读
目的探讨采用左乙拉西坦进行小儿热性惊厥复发预防治疗的临床效果及其安全性。方法随机选取郑州市第二人民医院2013年9月—2015年4月期间收治的热性惊厥反复发作患儿68例,按照入院先后顺序将其分为对照组和观察组,其中对照组患儿在其体温上升至38.5℃时行退热治疗,观察组患儿在对照组的治疗基础上,给予患儿左乙拉西坦口服治疗,对两组患儿的惊厥复发情况、发热情况及并发症的发生情况进行观察记录。结果观察组患儿的复发率明显低于对照组,其热性惊厥复发次数、发热发作次数均明显少于对照组患儿,差异具有显著性(P<0.05);两组患儿药物不良反应的发生率相比并无明显差异(P>0.05)。结论采用左乙拉西坦进行小儿热性惊厥的预防治疗,效果显著,能够有效将其患儿热性惊厥的复发率及发作次数,对于改善患儿的生存质量具有十分重要的临床意义,建议在临床上进一步推广。
Objective To investigate the clinical efficacy and safety of levetiracetam in the prevention and treatment of pediatric febrile seizures. Methods Sixty-eight children with recurrent febrile seizures admitted to the Second People’s Hospital of Zhengzhou City from September 2013 to April 2015 were randomly selected and divided into control group and observation group according to the order of their admission. Among them, the control group The body temperature rose to 38.5 ℃ when the antipyretic treatment, the observation group of children in the control group based on the treatment of children given levetiracetam oral treatment of children with recurrent seizures, fever and complications Occurrence of disease observation records. Results The recurrence rate of the observation group was significantly lower than that of the control group. The number of recurrences of febrile seizures and the number of fever attacks were significantly less than those of the control group, the difference was significant (P <0.05); two groups of children with adverse drug reactions The incidence was no significant difference (P> 0.05). Conclusions Levetiracetam can prevent and treat pediatric febrile seizures with significant effect and can effectively reduce the recurrence rate and number of seizures in children with febrile seizures, which is of great clinical significance for improving the quality of life in children. In the clinical further promotion.